Search hospitals > Quebec > MONTREAL
Novartis Investigative Site
Claim this profileMONTREAL, Quebec H3T 1E2
Global Leader in Breast Cancer
Global Leader in Adult T-Cell Leukemia/Lymphoma
Conducts research for Primary Lateral Sclerosis
Conducts research for Multiple Sclerosis
Conducts research for Parotid Gland Cancer
289 reported clinical trials
0 medical researchers
Summary
Novartis Investigative Site is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Breast Cancer, Adult T-Cell Leukemia/Lymphoma, Primary Lateral Sclerosis, Multiple Sclerosis, Parotid Gland Cancer and other specialties. Novartis Investigative Site is involved with conducting 289 clinical trials across 320 conditions. There are 0 research doctors associated with this hospital, such as .Area of expertise
1Breast Cancer
Global LeaderStage III
Stage IV
HER2 negative
2Adult T-Cell Leukemia/Lymphoma
Global LeaderBCR-ABL1 positive
BCR-ABL positive
CD19 positive
Top PIs
Clinical Trials running at Novartis Investigative Site
Multiple Sclerosis
Breast Cancer
Prostatic Neoplasm
Prostate Cancer
Primary Lateral Sclerosis
Membranoproliferative Glomerulonephritis
Hypercholesterolemia
Vasculitis
Breast cancer
Pancreatic Cancer
Ofatumumab
for Multiple Sclerosis
The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context of disease-modifying treatment (i.e., ofatumumab). To that end, the study will use the patented investigational, Eye Tracking Neurological Assessment (ETNA-ProgMS) SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision.
Recruiting3 awards Phase 42 criteria
Remibrutinib vs Teriflunomide
for Multiple Sclerosis
This trial compares two medications, remibrutinib and teriflunomide, for treating patients with relapsing multiple sclerosis. These patients have repeated episodes of symptoms and need effective treatments. The medications work by controlling the immune system to prevent it from causing damage to the nervous system. Teriflunomide is an approved medication for adults with relapsing multiple sclerosis.
Recruiting2 awards Phase 3
YTB323
for Multiple Sclerosis
This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.
Recruiting1 award Phase 1 & 26 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Novartis Investigative Site?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.